Financing ·
Tango Therapeutics, Inc. entered into an underwriting agreement on June 9, 2026, to conduct an underwritten offering…
TNGXTango Therapeutics, Inc.
Tango Therapeutics, Inc. entered into an underwriting agreement on June 9, 2026, to conduct an underwritten offering of 18,166,667 shares of common stock at $30.00 per share and 1,833,395 pre-funded warrants at $29.999 per warrant. The offering includes a 30-day option for underwriters to purchase up to 3,000,009 additional shares. The company expects net proceeds of approximately $566.5 million, which it intends to use for research and development, pivotal trial expenses, and general corporate purposes. Management believes these funds will extend its operating runway into 2030. Tango Therapeutics is a biotechnology company focused on developing precision medicines.